1st Half 2011
Sustained rebound in sales
The Group rebounded strongly from the end of 2010 on renewed growth momentum in first half of this year. Sales were up 3% in Europe and 23% in other regions from last year’s first half, with significant sales growth for Lipiodol in the US. Sales outside Europe accounted for 75% of the Group's growth.